Antengene SCLC trispecific antibody

Antengene's undisclosed trispecific antibody for small cell lung cancer (SCLC) is a therapeutic candidate developed using the company's proprietary **AnTenGager™ TCE 2.0 platform**. As a T-cell engager (TCE), the antibody is designed to bridge T-cells with tumor cells, facilitating targeted immune-mediated destruction of the cancer. While the specific tumor-associated antigens targeted by this molecule have not been publicly disclosed, the trispecific format typically allows for enhanced binding specificity or the incorporation of costimulatory domains to improve the therapeutic window and anti-tumor activity. The program is currently in the preclinical stage of development as part of Antengene's broader portfolio of multi-specific biologics.